Corpay Progresses Divestiture Program
Corpay expects to receive approximately $60 million in proceeds from the divestiture and free up approximately $35 million of working capital. Corpay plans to redeploy the capital towards its acquisition of Alpha Group International plc.
'This transaction is consistent with our plan to remix our portfolio towards higher growth Corporate Payments assets. It demonstrates our discipline to seek contract renewals only when economic terms are attractive,' said Ron Clarke, Chairman and CEO of Corpay.
The transaction is expected to close in the fourth quarter of 2025 and represents an immaterial contribution to earnings.
About Corpay
Corpay (NYSE: CPAY), the Corporate Payments Company, is a global S&P 500 provider of commercial cards (e.g, business cards, fleet cards, virtual cards) and AP automation solutions (e.g., invoice and payments automation, cross border payments) to businesses worldwide. We help businesses buy things and pay for things. Our solutions 'keep business moving' and result in our customers better controlling purchases, mitigating fraud, and ultimately spending less. To learn more visit www.corpay.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
10 minutes ago
- Cision Canada
Hospitality Gets High-Tech: The Future of Hotel Investment Is AI Automation
NEW YORK, Aug. 4, 2025 /CNW/ -- The hospitality industry is undergoing a major transformation powered by artificial intelligence (AI) and robotics, with hotels using automation reporting 30–40% reductions in operational costs, improved guest experiences and better revenue management. The AI in hospitality market size is expected to see exponential growth to $1.46 billion in 2029 at a compound annual growth rate (CAGR) of 57.8% while the global hospitality robotics market is projected to grow from $24.38 billion this year to $107.24 billion in 2034. Leading this shift is Nightfood Holdings Inc. (OTCQB: NGTF) (Profile), a pioneer hospitality entity that combines hotel ownership with AI-driven Robotics-as-a-Service (RaaS) The company recently announced plans to acquire a 155-room Holiday Inn in Victorville, California, its first model property integrating guest-facing robots such as food-delivery concierges and laundry assistants, a proprietary system provided by SGTF subsidiary Skytech. Nightfood has also established a strategic partnership with Bear Robotics to scale automation across its portfolio, which includes an estimated $80 million in assets. Nightfood joins a growing number of leading companies, including Tesla Inc. (NASDAQ: TSLA), SoFi Technologies Inc. (NASDAQ: SOFI), NVIDIA Corp. (NASDAQ: NVDA) and UiPath Inc. (NYSE: PATH), that are leveraging groundbreaking AI and robotics to innovate in their respective industries. Nightfood Holdings is a pioneer hospitality entity that combines hotel ownership with AI-driven Robotics-as-a-Service (RaaS). The company is strategically assembling an $80 million portfolio of institutional-grade hotels through targeted acquisitions. NGTF is executing a dual-revenue strategy that pairs recurring RaaS income with long-term real estate value creation. Nightfood Holdings is capitalizing on a first-mover advantage by integrating robotics and AI into hotel operations at a foundational level. With a seasoned team of executives who have developed more than 50 hotels and managed more than 130 hospitality assets, Nightfood Holdings brings deep industry expertise to every aspect of its growth strategy. Click here to view the custom infographic of the Nightfood Holdings editorial. AI, Robotics Revolutionizing Hospitality Business Research reports that "AI is transforming the hotel industry by optimizing revenue management, personalizing guest experiences, enhancing cybersecurity, and automating operations." The report notes that future AI in the hotel industry, which includes AI-driven sustainability, biometric check-ins, metaverse hotel previews and more, will lead to compound annual growth rate (CAGR) of more than 50% in the space in the coming years. Market Research Futures projects that the hospitality robot market will experience a CAGR of more than 71% through 2034 with robotics in hospitality seeing rising levels of trust, acceptance and understanding. "Guests are increasingly demanding personalized experiences when they travel," the report states. "They want to be able to tailor their stay to their own needs and preferences. Hospitality robots can help to provide personalized guest experiences by offering a variety of services, such as personalized recommendations for restaurants, activities, and attractions; real-time information about hotel amenities and services; the ability to control their room temperature, lighting and other settings. By providing personalized guest experiences, hospitality robots can help to increase guest satisfaction and loyalty." These impressive trajectories reflect widespread adoption across hotels, resorts, restaurants and cruise operations seeking cost savings, enhanced service and recovery from staffing shortages. Smart companies such as Nightfood Holdings are capitalizing on these trends, leveraging their expertise and resources to become leaders in the hospitality transformation. A Bold Real Estate Vision Nightfood Holdings is strategically assembling an $80 million property portfolio through targeted acquisitions, creating a scalable foundation for its next-generation hospitality platform. By acquiring high-visibility, branded properties in key growth markets, the company is focused on creating a strategic collection of real estate and leading the way in operational innovation. This focused expansion not only builds asset value but also allows for consistent delivery of elevated guest experiences and operating efficiency. Nightfood just announced that it is "on track to finalize due diligence and enter definitive agreements for the acquisition of two flagship hotel properties in Victorville and Rancho Mirage, California. Combined, these transactions represent approximately $80 million in institutional-grade real estate assets and serve as a cornerstone of the company's vertically integrated hospitality and automation strategy." The 155-room Victorville property is currently a Holiday Inn. Nightfood earlier signed a letter of intent to purchase the property for approximately $41 million, with plans to convert it into a Courtyard by Marriott. The hotel will serve as a flagship property in the company's portfolio, showcasing operational enhancements and property upgrades intended to boost revenue and brand recognition. Victorville's strategic location, along one of the busiest transportation corridors between Los Angeles and Las Vegas, positions the property for strong occupancy and long-term performance. Building on that momentum, Nightfood signed a second letter of intent to acquire a Hilton Garden Inn in Rancho Mirage, California, for roughly $37 million. The property sits adjacent to Disney's highly anticipated Cotino residential and resort development, a location expected to benefit from substantial traffic and tourism in the coming years. By investing in a branded, upscale asset in such a premium corridor, Nightfood is enhancing both the value and visibility of its growing portfolio. According to the company, both properties will be integrated into Nightfood's AI automation platform, serving as operational environments for robotic deployments, data collection and revenue optimization. Together, these acquisitions demonstrate the company's focus on institutional-quality assets with strong brand affiliations and location advantages. Each addition to the portfolio is carefully selected to support scalability, ensure stable cash flow and serve as a platform for long-term growth. As Nightfood continues to expand its holdings, it is creating a strong and differentiated position in the hospitality real estate space, anchored by quality, operational excellence and future-ready infrastructure. Nightfood Holdings is executing a dual-revenue strategy that pairs recurring RaaS income with long-term real estate value creation. At the core of this approach is the deployment of AI-powered service robots that automate essential hospitality functions, such as food and amenity delivery, linen transport and cleaning, across the company's hotel properties. These robotic systems are offered on a subscription basis, creating a predictable and scalable revenue stream that is not tied to seasonal occupancy or nightly rates. Through its Skytech Automated Solutions division, Nightfood is developing and installing robots specifically engineered for the hospitality sector. These include concierge robots that interact directly with guests, autonomous carts that transport laundry and supplies, and cleaning bots that operate efficiently in common areas. By reducing labor demands and increasing operational efficiency, RaaS technology enables hotels to streamline staffing, cut costs and improve the guest experience, all while generating monthly recurring revenue. This recurring revenue model is being embedded into properties the company is acquiring, including its planned flagship hotels in Victorville and Rancho Mirage, California. These hotels will serve as model sites where the RaaS platform can be refined and demonstrated at scale. The ultimate goal is to license and deploy Nightfood's robotic systems across a broader network of third-party hotel operators, enabling expansion of the RaaS model beyond company-owned properties. By combining high-impact automation with direct ownership of real estate assets, Nightfood is creating a vertically integrated business model. The RaaS component delivers consistent, technology-driven revenue, while hotel ownership provides asset appreciation and brand equity. This synergy positions the company to benefit from both short-term income and long-term value creation in a transforming hospitality landscape. Pioneering the Future of Tech-Enabled Hospitality Nightfood Holdings is capitalizing on a first-mover advantage by integrating robotics and AI into hotel operations at a foundational level. Through its proprietary RaaS platform, the company is deploying guest-facing and back-of-house service robots that perform tasks such as food and linen delivery, cleaning and concierge support. These robotic systems are not add-ons but core operational components, designed to streamline workflows, reduce labor costs and enhance the overall guest experience. By owning and operating its initial properties, Nightfood can rapidly prototype and refine its automation technologies in live environments before offering them to third-party operators. This vertically integrated strategy allows for the seamless fusion of real estate operations with tech deployment, creating a hospitality model that is both operationally efficient and easily scalable. Unlike traditional hotel-management companies or pure-play robotics firms, Nightfood is positioned to generate recurring revenue from automation while also benefiting from asset value appreciation. With pilot programs underway and a growing ecosystem of robotics, AI and strategic partnerships, the company is laying the groundwork for broad market adoption, setting a new standard for how hotels operate in the AI era. Experienced Leadership Driving Strategic Growth With a seasoned team of executives who have developed more than 50 hotels and managed more than 130 hospitality assets, Nightfood Holdings brings deep industry expertise to every aspect of its growth strategy. The leadership team combines decades of experience in hotel operations, finance and real estate development, enabling the company to identify high-potential properties, negotiate favorable deal terms and execute value-enhancing improvements with precision. This hands-on knowledge ensures that acquisitions are not only strategic but also aligned with long-term growth and operational efficiency. The company's strong operational background also facilitates effective integration of new properties into the portfolio while maintaining high standards of service and performance. Nightfood's disciplined approach to capital allocation underpins its ability to scale without overextending. Each acquisition is selected based on rigorous financial modeling, brand potential, and operational upside. By targeting institutional-grade assets in markets with long-term demand drivers, Nightfood ensures both stability and room for innovation. This measured approach minimizes risk while maximizing value creation, allowing the company to balance growth ambitions with sustainable financial management. Paired with its focus on technology integration and recurring revenue through automation, the company's leadership is executing a clear, focused strategy that balances growth with financial prudence and positions it well for long-term success. Shaping the Future with AI, Robotics In addition to Nightfood's innovation, recent announcements from top-tier tech companies highlight a pivotal moment in the evolution of AI and robotics. As these industry innovators integrate advanced AI systems into their offerings, they are not only enhancing performance and efficiency but also establishing themselves at the forefront of a rapidly evolving global market. Tesla Inc. announced its most recent developments in AI and robotics during its Q2 2025 earnings report. "Q2 2025 was a seminal point in Tesla's history: the beginning of our transition from leading the electric vehicle and renewable energy industries to also becoming a leader in AI, robotics and related services," the report stated. "Our first Robotaxi service launched in Austin in June. While the service is limited in scope, we believe our approach to autonomy, a camera-only architecture with neural networks trained on data from our global fleet of millions of vehicles, allows us to continually improve safety, rapidly scale the network and improve profitability." SoFi Technologies Inc. announced that it expanded access to alternative investments funds to provide investors with exposure to multiple private companies that include AI. The company is leveling the financial playing field by offering investment minimums starting at $10. The announcement noted that SoFi has partnered with Templum to give members access to privately held companies via the Cosmos Fund, with asset classes offering sole exposure to top tech companies including SpaceX, Databricks and xAI. NVIDIA Corp. has released NVIDIA Isaac GR00T N1.5, the first update to the company's open, generalized, fully customizable foundation model for humanoid reasoning and skills; NVIDIA Isaac GR00T-Dreams, a blueprint for generating synthetic motion data; and NVIDIA Blackwell systems to accelerate humanoid robot development. "Physical AI and robotics will bring about the next industrial revolution," said Jensen Huang, founder and CEO of NVIDIA. "From AI brains for robots to simulated worlds to practice in or AI supercomputers for training foundation models, NVIDIA provides building blocks for every stage of the robotics development journey." UiPath Inc. has been recognized as a leader in the 2025 Gartner(R) Magic Quadrant(TM) for Robotic Process Automation. This marks the seventh consecutive year UiPath has earned this distinction, with the company being positioned highest for its ability to execute. Gartner's evaluation highlighted UiPath's leadership in agentic automation, where intelligent software agents can perceive, reason and act autonomously to achieve complex business objectives. This recognition underscores UiPath's ongoing commitment to advancing AI-driven automation solutions. Together, these companies reflect the breadth and impact of AI integration across sectors. As the AI and robotics revolution continues to unfold, these advancements signal a profound transformation in how we live, work and invest. For more information, visit Nightfood Holdings (NGTF). NetworkNewsWire ("NNW") is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge. For more information, please visit Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: NetworkNewsWire is powered by IBN DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
Cision Canada
10 minutes ago
- Cision Canada
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
NEW YORK, Aug. 4, 2025 /CNW/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration's "Make America Healthy Again" initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) (Profile) is making strides with its HyBryte(TM) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte's active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. The company is one of several impressive companies committed to making an impact in the pharmaceutical space, including Pfizer Inc. (NYSE: PFE), Merck & Co Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY) and Insmed Inc. (NASDAQ: INSM). Soligenix Inc.'s HyBryte platform represents a promising therapeutic option for cutaneous T-cell lymphoma, a rare cancer that often affects older adults. A second confirmatory phase 3 clinical trial for HyBryte is underway and represents a pivotal step in advancing the therapy toward global commercialization for the treatment of early-stage CTCL. HyBryte received both U.S. and EU orphan drug designations as well as Fast Track status from the FDA, underscoring the serious unmet medical need it addresses. A critical attribute of HyBryte in the treatment of CTCL is its consistently strong safety profile, demonstrated across multiple clinical studies. Click here to view the custom infographic of the Soligenix Inc. editorial. Continued Investment in Rare Diseases Is Key Chronic rare diseases are emerging as a major challenge within the aging U.S. population. As life expectancy increases, so too does the complexity of healthcare needs, particularly when it comes to conditions that are both long-lasting and difficult to diagnose. Tens of millions of Americans are facing life with a rare disease, and many of them are seniors whose symptoms can easily be dismissed as normal signs of aging. Because rare diseases often present subtly or mimic more common age-related issues, diagnosis in older adults can be delayed by years, hindering access to effective care and worsening outcomes. Compounding the issue is the limited availability of FDA-approved treatments. With thousands of rare diseases identified, the vast majority remain without approved therapies, underscoring the importance of continued investment in research and development. Seniors, in particular, are vulnerable to underdiagnosis and undertreatment, especially when the healthcare system is not attuned to the nuanced presentation of rare conditions in older adults. In response, the "Make America Healthy Again" initiative has spotlighted the growing burden of chronic and rare diseases. Through targeted policies aimed at accelerating research, improving diagnostic tools and expanding access to care, these efforts seek to address the needs of older Americans grappling with complex, often overlooked, health challenges. Companies such as Soligenix Inc. are rising to meet this need. The firm's HyBryte program represents a promising therapeutic option for cutaneous T-cell lymphoma, a rare cancer that often affects older adults. Soligenix has recently completed the successful U.S. manufacturing transfer of HyBryte's active ingredient, advancing its mission to bring effective, innovative treatments to patients most in need. A Rare Cancer with Unmet Needs Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin's lymphoma (NHL) that primarily affects the skin. Unlike other lymphomas, CTCL involves malignant T-cells that migrate to the skin's surface, forming patches, lesions or tumors. This chronic cancer most commonly appears in older adults, making it particularly relevant to the aging population. Despite its rarity, CTCL remains a serious medical concern, affecting more than 40,000 NHL patients globally. There is currently no known cure for CTCL, and treatment is often limited to managing symptoms and slowing disease progression. The most prevalent subtype of CTCL is mycosis fungoides (MF), which accounts for approximately 90% of all CTCL cases. In its early stages (I–IIA), MF has a relatively high five-year survival rate of 88%, but it remains a lifelong illness. As a chronic condition with no approved first-line therapy for early-stage patients, CTCL represents a clear unmet medical need. The global market opportunity for CTCL therapies in the seven major markets (the United States, EU4, the United Kingdom and Japan) was estimated at about $995 million in 2024, with the U.S. accounting for some 70% of that. In addition, DelveInsight notes that "the expected launch of therapies such as HyBryte . . . will also boost the CTCL market growth." Without these new therapies, effective treatment options remain limited, especially for those diagnosed in the early stages. Many patients undergo a series of therapies with limited success, underscoring the need for innovative, targeted treatments. Soligenix's HyBryte (synthetic hypericin) offers a promising solution as a potential first-line therapy for early-stage CTCL. By addressing this critical gap in care, HyBryte has the potential to significantly improve quality of life for thousands of patients and become a leading treatment option in this underserved market. Bolstering the Case for HyBryte Soligenix's second confirmatory phase 3 clinical trial for HyBryte, known as FLASH2, is currently underway and represents a pivotal step in advancing the therapy toward global commercialization for the treatment of early-stage CTCL. Designed to reinforce the positive findings of the initial FLASH study, FLASH2 has been accepted by the European Medicines Agency (EMA), while discussions with the U.S. Food and Drug Administration (FDA) remain ongoing. This validation by European regulators underscores the robustness of the trial design and its alignment with international standards for therapeutic approval. The FLASH2 study maintains a similar structure to its predecessor but features an extended double-blind, placebo-controlled treatment duration of 18 weeks, three times longer than the original six-week period in the first FLASH trial. This longer timeline is expected to provide even more comprehensive data on HyBryte's safety and efficacy. Importantly, key elements such as the patient inclusion and exclusion criteria and the primary endpoint remain consistent between the two studies, supporting the integrity and comparability of the trial outcomes. Approximately 80 patients will be enrolled across clinical sites in both the United States and Europe. This multinational approach is intended to support broad regulatory submissions and pave the way for HyBryte's commercial launch on a global scale. With enrollment progressing on schedule, Soligenix anticipates reporting top-line results in 2026, data that could significantly bolster the case for HyBryte as the first approved front-line treatment for early-stage CTCL. As Soligenix continues to advance this promising therapy, FLASH2 stands as a potentially transformational milestone in the company's effort to address a long-standing unmet medical need within the rare disease and oncology communities. A Critical Advancement in Treatment Soligenix's HyBryte achieved positive, statistically significant results in its first phase 3 clinical trial, known as the FLASH study, marking a critical advancement in the treatment of early-stage CTCL. HyBryte received both U.S. and EU orphan drug designations as well as Fast Track status from the FDA, underscoring the serious unmet medical need it addresses. Unlike many CTCL therapies that require a year or more to demonstrate efficacy, HyBryte showed a statistically significant treatment response in just six weeks, with response rates improving to 40% at 12 weeks and 49% at 18 weeks. The therapy demonstrated effectiveness across both patch and deeper plaque lesions, an important distinction given that many current early-stage CTCL treatments are primarily effective only on patch-type manifestations. This broader lesion response highlights HyBryte's unique therapeutic potential within a complex and varied disease presentation. The study's design and outcomes also reflect the treatment's clinical promise as a practical, noninvasive solution that could change the standard of care for CTCL patients. Safety and tolerability further set HyBryte apart. The FLASH trial reported minimal adverse events, a significant benefit when compared to other CTCL therapies that are often associated with both acute and chronic side effects. This favorable safety profile may make HyBryte especially appealing to older patients who are frequently managing multiple health conditions. Additionally, HyBryte's use of visible fluorescent light rather than ultraviolet (UV) light avoids the carcinogenic risks typically associated with conventional phototherapy. This novel light-based activation of synthetic hypericin enhances patient safety while maintaining therapeutic efficacy. Collectively, the FLASH and FLASH2 study results position HyBryte as a strong candidate to become the first approved front-line treatment for early-stage CTCL, offering a faster, safer, and more effective alternative to existing therapies. Consistent, Strong and Safe A critical attribute of HyBryte in the treatment of CTCL is its consistently strong safety profile, demonstrated across multiple clinical studies. Unlike many current therapies for early-stage CTCL, which are typically associated with severe and sometimes fatal side effects, HyBryte has been well tolerated and shows no evidence of safety concerns to date. Its mechanism of action is not linked to DNA damage, a significant distinction that positions it as a potentially safer alternative in a treatment landscape where many options carry risks such as melanoma, other malignancies, severe skin damage and premature skin aging. This favorable safety profile is especially relevant given that all currently available CTCL therapies are only approved following the failure of other treatments, and none have been approved for front-line use. In this context, safety becomes a decisive factor in selecting a treatment course, particularly for older adults who are often managing multiple health conditions. HyBryte's minimal systemic absorption, non-mutagenic compound and use of a non-carcinogenic visible light source make it uniquely positioned as a safe and effective treatment option. As the CTCL community awaits a first-line therapy, HyBryte stands out as a promising candidate capable of meeting both efficacy and safety demands. In addition to its strong clinical profile, HyBryte represents a significant commercial opportunity in an area of high unmet medical need. With an estimated global CTCL market potential exceeding $990 million, the therapy is well positioned to address a meaningful segment of the CTCL population. As development advances, HyBryte offers the potential not only to improve patient outcomes but also to establish itself as a valuable new standard in CTCL treatment. Advancing Rare Disease Care In an era where precision medicine and urgent unmet needs converge, several pharmaceutical leaders are stepping up with bold new advances in cancer and complex disease treatment, from improving survival outcomes in prostate and lung cancer to advancing novel therapies for pulmonary hypertension. These developments reflect a broader commitment across the life sciences industry to accelerate innovation and deliver life-extending, quality-of-life-enhancing options for patients with high-need conditions. Pfizer Inc. is reporting positive topline results from the overall survival (OS) analysis from its phase 3 EMBARK study. The study evaluated XTANDI(R) (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with biochemical recurrence (BCR) at high risk for metastasis. The announcement was made with Astellas Pharma U.S. Inc. XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in nmHSPC with high-risk biochemical recurrence BCR. Merck & Co Inc. announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial. The phase 3 study evaluates the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) with disease progression during or after treatment with an androgen receptor pathway inhibitor. I-DXd is being jointly developed by Merck and Daiichi Sankyo. While localized prostate cancer has a five-year survival rate of more than 90%, survival decreases to 31% in the advanced or metastatic stage, the company noted, reinforcing the need for new approaches to improve outcomes. Bristol-Myers Squibb Co. has received critical approval from the European Commission (EC) for a key perioperative regimen. The regimen is for neoadjuvant Opdivo (R) (nivolumab) and chemotherapy followed by surgery and adjuvant Opdivo for the treatment of resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adult patients whose tumors have PD-L1 expression ≥1%. The EU approval is based on results from the CheckMate-77T trial, which showed perioperative Opdivo improved event-free survival compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo. Insmed Inc. announced positive topline results from its randomized, double-blind, placebo-controlled phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension (PAH). According to the announcement, the study met primary and all secondary efficacy endpoints. Insmed noted that it plans to immediately engage with the U.S. Food and Drug Administration regarding a phase 3 trial design for PAH. Insmed plans to initiate a phase 3 trial in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) before the end of 2025 and a phase 3 trial in patients with PAH in early 2026. These announcements spotlight the momentum building across rare-disease research, with these companies contributing key pieces to the larger puzzle of patient-centered medical breakthroughs. As regulatory engagement continues and phase 3 trials advance, the coming years may bring meaningful shifts in standard-of-care therapies, offering hope to patients facing some of the most challenging diagnoses in medicine today. For more information, visit Soligenix Inc. NetworkNewsWire ("NNW") is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge. For more information, please visit Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: NetworkNewsWire is powered by IBN DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
Cision Canada
40 minutes ago
- Cision Canada
DXC and 7AI Partner to Deliver Revolutionary AI-Powered Security Operations Service
New agentic security service reduces operational costs through autonomous AI agents while delivering faster response times and scaling coverage In 2025, 7AI's platform has saved security teams 224,000 analyst hours – equivalent to approximately 112 analyst years of work and $11.2 million LAS VEGAS, August 4, 2025 /CNW/ - DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services company, and 7AI, a leader in agentic security, today announced a strategic partnership to launch DXC Agentic Security Operations Center (SOC). As a category-defining moment, DXC will now integrate fully autonomous AI agents into its end-to-end managed security operations – from alert ingestion, through investigation to remediation – delivering enhanced speed, accuracy, and coverage for its customers globally. Additionally, DXC has implemented 7AI's platform to optimize its internal SOC capabilities. In the next few years, AI is expected to reshape security operations and significantly automate and transform core SOC tasks. DXC and 7AI's partnership represents a fundamental shift in how managed security services are delivered, moving beyond traditional manual approaches to leverage 7AI's specialized AI agents that autonomously handle alert triage, threat investigation, and incident response. The new DXC Agentic SOC will be available to customers worldwide and delivers measurable improvements in security outcomes across speed, scale, and cost. By leveraging 7AI's platform, DXC Agentic SOC eliminates the traditional bottlenecks of manual alert processing, expecting to save customers 30 minutes to 2.5 hours per investigation reduce false positive rates that can consume analyst resources. "The use of AI enhances security efforts by boosting efficiency, augmenting human skills, and enabling SOCs to scale and deliver greater value in the face of growing cyber threats," said Chris Drumgoole, President, Global Infrastructure Services at DXC. "The future of security operations isn't about more tools or more automation, it's about intelligent AI agents that deliver measurably better outcomes. By partnering with 7AI, we're pioneering the next phase of managed security services, delivering better insights, faster response times and, ultimately, superior protections for our customers." Across 7AI's customer base, the 7AI platform has already saved security teams over 224,000 analyst hours – equivalent to 112 full-time analyst years of work and more than $11.2 million in reclaimed productivity. With the platform projected to save customers over $100 million in 2025, according to 7AI, the company's Dynamic Reasoning innovation autonomously determines the appropriate investigative approach for novel, never-before-seen threats in real time - without requiring pre-written playbooks or rules. Customers will benefit from DXC's security experts for implementation and ongoing support, as well as incident response and breach management services to ensure rapid remediation. Additionally, as part of its managed service, DXC's extensive network provides anonymized threat patterns and intelligence that enhance 7AI, improving detection capabilities while maintaining strict client data protection. This includes comprehensive governance, risk, and compliance services, tailored to the unique needs of each customer. "DXC's global cybersecurity scale - serving hundreds of customers, across 25 delivery centers that process 4.5 million daily security threats – provide the real-world data environment essential for advancing our AI. This combination of proven security leadership and operational breadth makes DXC the ideal partner for delivering truly agentic security solutions to the enterprise market," said Lior Div, CEO and Co-Founder of 7AI. "This partnership validates our vision for a new era where security teams can focus exclusively on security outcomes. DXC customers will experience what it means to have AI agents that continuously improve their understanding of each organization's unique security context." Experience the Future at Black Hat 2025 Customers and prospects can experience live demonstrations of DXC Agentic SOC at the 7AI booth (#1940) and visit DXC in the AI Pavilion (booth 4412) during Black Hat 2025, August 3-8 in Las Vegas. The announcement at Black Hat reinforces DXC's position as a cybersecurity innovator, showcasing live autonomous AI investigations that traditionally require hours of manual analyst work. DXC representatives will be available to discuss implementation, customization options, and integration with existing DXC services. To learn more about DXC Agentic SOC, visit About DXC Technology DXC Technology (NYSE: DXC) is a leading global provider of information technology services. We're a trusted operating partner to many of the world's most innovative organizations, building solutions that move industries and companies forward. Our engineering, consulting and technology experts help clients simplify, optimize and modernize their systems and processes, manage their most critical workloads, integrate AI-powered intelligence into their operations, and put security and trust at the forefront. Learn more on About 7AI 7AI is the leader in agentic security, delivering the industry's first agentic security platform that harnesses specialized AI agents to autonomously handle essential security operations tasks. Founded in 2024 by cybersecurity veterans Lior Div and Yonatan Striem-Amit, creators of Cybereason, 7AI enables security teams to shift from reactive, manual processes to proactive, autonomous defense. The company's Dynamic Reasoning technology allows AI agents to adapt their decision-making based on contextual understanding of each unique security scenario, eliminating false positives and delivering actionable conclusions at machine speed. Backed by Greylock Partners, Spark Capital, and CRV, 7AI empowers security leaders to position their organizations at the forefront of the AI transformation. For more information, visit
